Division of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale, Napoli, Italia.
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12480-12489. doi: 10.26355/eurrev_202012_24044.
COVID-19 disease is one of the biggest public health challenges in Italy and global healthcare facilities, including radiotherapy departments, faced an unprecedented emergency. Cancer patients are at higher risk of COVID-19 infection because of their immunosuppressive state caused by both tumor itself and anticancer therapy adopted. In this setting, the radiation therapy clinical decision-making process has been partly reconsidered; thus, to reduce treatment duration and minimize infection risk during a pandemic, hypofractionated regimens have been revised. Moreover, telemedicine shows its helpfulness in the radiotherapy field, and patients get the supportive care they need minimizing their access to hospitals. This review aims to point out the importance of hypofractionated RT and telemedicine in cancer patient management in the COVID-19 era.
COVID-19 疾病是意大利乃至全球医疗保健机构面临的最大公共卫生挑战之一，包括放射治疗部门在内，都面临着前所未有的紧急情况。癌症患者由于肿瘤本身和所采用的抗癌治疗导致免疫抑制状态，因此感染 COVID-19 的风险更高。在这种情况下，放射治疗的临床决策过程已经部分重新考虑；因此，为了减少治疗时间并在大流行期间最大限度地降低感染风险，已经修订了分段治疗方案。此外，远程医疗在放射治疗领域显示出其有益性，患者可以获得所需的支持性护理，最大限度地减少他们前往医院的次数。这篇综述旨在指出在 COVID-19 时代，分段治疗和远程医疗在癌症患者管理中的重要性。
